Aparito
Aparito provides the Atom5™ eCOA platform for decentralised clinical trials, capturing real-world data via video assessments, wearable devices, and ePROs in 125 languages across 193 countries. Founded in 2014 in Wrexham, Wales, and operating as a wholly owned subsidiary of Eli Lilly and Company since May 2024.
- Company typePrivate
- Founded2014
- HeadquartersWrexham, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Aparito does
Aparito Limited is a UK-based digital health company headquartered in Wrexham, Wales, founded in 2014 by Dr. Elin Haf Davies to digitise clinical trials and capture real-world data via its Atom5™ eCOA (electronic Clinical Outcome Assessment) platform. The platform unifies video assessments, ePROs, telemedicine, eConsent, and wearable device integrations across iOS, Android, and web clients, and supports over 800 configurations with questionnaires available in 125 languages for deployment in 193 countries. Atom5™ is ISO 13485 and ISO/IEC 27001:2016 accredited and compliant with FDA 21 CFR Part 11, HIPAA, GDPR, and Cyber Essentials Plus, positioning it as sponsor-grade infrastructure for decentralised and hybrid clinical trials. The company's proprietary technology stack applies computer vision (including OpenPose-based pose estimation) and machine learning to extract objective, validated digital endpoints from patient-recorded video, with branded vCOAs including SARAhome (ataxia), vTUG (Timed Up-and-Go), vHOT, FEEDS (paediatric feeding), and DMDhome (Duchenne Muscular Dystrophy).
Aparito monetises primarily through enterprise SaaS-style study-by-study licensing of Atom5™ to pharmaceutical sponsors and CROs, supplemented by professional services from its data science team (computer vision, image/signal processing, time-series ML) and co-development engagements through the Patient Group Accelerator Programme, which partners with patient advocacy organisations (Duchenne UK, ALS Liga Belgium, International Gaucher Alliance) to develop disease-specific digital biomarkers for orphan indications. Pricing is quote-based and not publicly disclosed. The company serves pharmaceutical sponsors and CROs as its primary commercial segment, with academic clinical research groups, NHS and international hospitals, and patient advocacy groups as secondary segments. Since May 2024, Aparito has operated as a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), with the founder and all staff retained and operations continuing from Wrexham; the deal delivered a profitable exit to the Development Bank of Wales and gave Aparito embedded distribution into one of the world's largest pharmaceutical pipelines.
Aparito firmographics
Firmographics- Name
- Aparito
- Legal name
- Aparito Limited
- Website
- https://aparito.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Aparito provides the Atom5™ eCOA platform for decentralised clinical trials, capturing real-world data via video assessments, wearable devices, and ePROs in 125 languages across 193 countries. Founded in 2014 in Wrexham, Wales, and operating as a wholly owned subsidiary of Eli Lilly and Company since May 2024.
- Ownership category
- akta.pro rank
Aparito industry classification
Industry- Product category
- Clinical Trial Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Pharmaceutical Preparations (2834), Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Electronic Data Capture (EDC) Platforms (HLACAOAA)
- akta.pro secondary industries
- eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB), Patient App, Adherence & Engagement for RPM Programs (HLACAFAJ), ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history) (HLALAIAD), Medication Adherence & Therapy Management Platforms (refills, reminders, MTM) (HLALAIAG), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where Aparito is headquartered
LocationHeadquarters
- HQ city
- Wrexham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Aparito business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Enterprise SaaS subscription (Atom5™ eCOA platform): Aparito licenses its Atom5™ eCOA platform to pharmaceutical sponsors and CROs on a study/subscription basis, configured per protocol with over 800 platform configurations supporting global hybrid/decentralised clinical trials.
- Professional services & data science consulting: Aparito's data science team provides analytical services including computer vision, image & signal processing, time series analysis and Machine Learning tooling to enhance sponsor data analysis plans and help formulate research questions.
- Patient Group Accelerator / co-development partnerships: Through its Patient Group Accelerator Programme, Aparito co-develops new digital biomarkers with patient organisations (e.g., DMD, PCD), generating long-tail pipeline of validated endpoints for subsequent clinical deployment.
- Enterprise software licensing / study configuration: Study-by-study platform licensing with configuration services for sponsors running decentralised or hybrid trials, with optional provisioned devices or BYOD model.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based enterprise licensing per study/trial |
Go-to-market motion5 records
Distribution channels4 records
Marketing channels7 records
Aparito product offering
Product offeringCore offering
Aparito provides the Atom5 eCOA (electronic Clinical Outcome Assessment) platform that digitizes clinical trials by capturing patient data via video assessments, ePROs (electronic Patient-Reported Outcomes), wearable devices, telemedicine, and eConsent. The platform supports decentralized and hybrid clinical trials for pharmaceutical sponsors, CROs, and academic research groups across 193 countries and 125 languages, with over 800 configurations and compliance to FDA 21 CFR Part 11, HIPAA, GDPR, ISO 13485, and ISO 27001.
Product overview
Aparito (a wholly owned subsidiary of Eli Lilly and Company) operates a unified decentralised clinical-trial technology stack anchored by its core Atom5™ eCOA Platform. Atom5™ is built as a platform-plus-modules architecture comprising Multi-Device Patient Data Capture, a Clinician and Sponsor Portal, an eCOA Library, and Data Management & Analytics, and supports ePROs, telemedicine, eConsent, and wearable integrations. Layered on top are video Clinical Outcome Assessment (vCOA) modules — vTUG, vHOT, SARAhome, DMDhome, and FEEDS — which use computer vision and machine learning to extract objective endpoints from patient-recorded video. Alongside this, AMP™ (Aparito Management Platform) provides an electronic Quality Management System (eQMS), and the Patient Group Accelerator Programme supports rare disease patient groups. The portfolio is positioned as a regulated, patient-centric decentralised trial platform (FDA 21 CFR Part 11, HIPAA, GDPR, ISO 27001, ISO 13485, Cyber Essentials Plus).
Differentiator
Problem solved
Functional benefit
Brands
- Atom5: Aparito's flagship eCOA (electronic Clinical Outcome Assessment) platform that captures patient data via Video Assessments, ePROs, Telemedicine, Wearables and eConsent, with over 800 configurations to adapt to global hybrid or decentralised study requirements.
- AMP (Aparito Management Platform)
Products and services
- Atom5 eCOA Platform
- AMP (Aparito Management Platform)
- Patient Group Accelerator Programme
- Professional Services & Data Science Consulting
Quantifiable outcome
- ePRO compliance rates of 90–97% compared with ≤30% for paper PROs
- +8 more outcomes
Companies that use Aparito
Customer profileNamed customers14 records
Segments6 records
Ideal customer profiles4 records
Aparito technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability9 records
Feature11 records
Aparito partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered research collaborator, flagship / parent company, mid-tier research partner, strategic (patient group accelerator), patient advocacy collaborator, core scientific, core strategic, patient group accelerator partner and technology integration layer.
- Headway UKresearch collaboratorPartnered on the PRiORiTy Usability Study — recruiting individuals with traumatic brain injury for usability testing of the Atom5™ ePRO platform via 'Think Aloud' cognitive interviews.
- Eli Lilly and Companyflagship / parent companyIn May 2024, US-based pharmaceutical company Eli Lilly and Company acquired UK-based Aparito Limited to strengthen capabilities in decentralised clinical trials and patient-centric data collection. Founder Dr Elin Haf Davies and all staff retained; Aparito continues to operate from Wrexham, Wales, as a wholly owned subsidiary of Eli Lilly. The partnership gives Aparito global distribution reach across Eli Lilly's pharmaceutical pipeline.
- PROFA Study consortium (Friedreich ataxia centres in Germany, France, Austria)mid-tier research partnerPan-European observational study (n=200) deploying SARAhome via the Atom5™ eCOA platform across six study centres in Germany, France and Austria to capture patient-reported, health economic and psychosocial outcomes in Friedreich ataxia.
- ALS Liga Belgiumstrategic (patient group accelerator)Aparito's Patient Group Accelerator and ALS Liga Belgium have collaborated to develop digital endpoints capturing meaningful aspects of health (MAH), concepts of interest (COI), and outcomes for ALS patients. Co-developed ALSHome digital outcome measures are tested for usability and clinical utility on the Atom5™ platform.
- International Gaucher Alliance (IGA)strategic (patient group accelerator)Co-developed GaRDIAN — the patient-led, patient-owned registry for neuronopathic Gaucher disease (nGD) — with Aparito's Elin Haf Davies as a key architect. The registry collects disease-specific patient-reported and observer-reported outcomes to inform regulatory real-world data needs.
- Long COVID SOS / Long COVID Scotland / Long COVID Supportpatient advocacy collaboratorPatient and public involvement and engagement (PPIE) partners who assisted with recruitment of study participants for the TLC Study using Atom5™ ePRO/eConsent, supporting the Nature Medicine publication on PPIE considerations.
- DZNE (Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.)core scientificCo-developed SARAhome — the video-based version of the Scale for the Assessment and Rating of Ataxia — with Dr Marcus Grobe-Einsler and team at DZNE. Validated in 526 spinocerebellar ataxia patients from EUROSCA, with the deployment also powered by machine-learning-based automatic speech rating.
- University of Birmingham (CPROR)core strategicAparito partners with the Centre for Patient Reported Outcome Research (CPROR) at the University of Birmingham to co-develop digital PROs for a wide range of disease groups, configure Atom5™ for patient quality-of-life and symptom assessment in clinical trials and routine NHS care, and inform regulators (MHRA) and policymakers (NICE). Joint work includes the Symptom Burden Questionnaire™ for Long COVID (TLC Study) and the ATMP basket trial ePRO (PROmics).
- Alexion, AstraZeneca Rare Diseasemid-tier research partnerJoint research exploring the role of video recording and analysis in rare disease drug development, including use of video in the development of asfotase alfa (Strensiq®) in hypophosphatasia and the development of SARAhome for ataxia. Co-authored the 'Time to See the Difference: Video Capture for Patient-Centered Clinical Trials' paper in The Patient journal.
- Red Cross War Memorial Children's Hospital & University of Cape Town (epilepsy / mHealth study)research collaboratorJoint feasibility study demonstrating mHealth technology potential to improve management of paediatric epilepsy in resource-limited South African settings, using the Atom5™ platform.
- Duchenne UKcore strategicAparito co-developed the DMDhome video-based approach with Duchenne UK, delivered through the Atom5™ platform, to assess motor function in patients with Duchenne Muscular Dystrophy. Pioneering work in computer vision analysis (OpenPose) of upper and lower limb function. Duchenne UK was one of the first two patient groups selected for Aparito's Patient Group Accelerator Programme.
- PCD Support UK (Primary Ciliary Dyskinesia)patient group accelerator partnerOne of the first two patient groups selected for Aparito's Patient Group Accelerator Programme alongside Duchenne UK, focused on developing digital endpoints and biomarkers for PCD.
- Wearable device manufacturers (integrated via API/SDK)technology integration layerAtom5™ integrates with any device that has an available API/SDK, including commercial-grade wearables such as the Garmin Venu 2 used in the digital 1-Minute Walk Test (1MWT) pilot study for pulmonary hypertension.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Aparito competitors and assessment
Company assessmentDirect peers
- Medidata Solutions: Medidata (a Dassault Systèmes company) is a leading eCOA and eClinical platform vendor serving the same pharmaceutical sponsors and CROs as Aparito. Its Rave eCOA suite is the most widely deployed direct competitor to Atom5™ in regulated clinical trials.
- Clario: Clario (formed by the merger of ERT and Bioclinica) is a major eCOA and clinical endpoint technology vendor offering electronic patient-reported outcomes, wearables and decentralised trial solutions directly competitive with Aparito's Atom5™ platform.
- Signant Health: Signant Health (formed from CRF Health and Bracket) provides eCOA, ePRO, rater training and patient engagement solutions for global clinical trials. Its eCOA platform directly competes with Aparito's Atom5™ for sponsor study wins.
- Science 37: Science 37 is a decentralised clinical trial operating model and platform competitor to Aparito, focused on enabling at-home patient participation in sponsor trials with similar eCOA, telemedicine and wearable capabilities.
- ObvioHealth: ObvioHealth runs fully decentralised clinical trials using its own eCOA platform with wearables, ePRO and remote monitoring — directly comparable to Aparito's Atom5™-enabled DCT offering for pharma sponsors.
Broad incumbents
- Oracle Health Sciences (Clinical One / Phase Forward): Oracle Health Sciences offers Clinical One eClinical platform and the legacy Phase Forward eCOA suite, serving large pharmaceutical sponsors with broader eClinical workflows in which eCOA is one component — a broad incumbent competing for the same sponsor budgets as Aparito.
- Veeva Systems: Veeva provides Vault eClinical, CTMS and CDB platforms to life sciences sponsors and CROs. While not eCOA-native, Vault competes with Atom5™ for sponsor platform budget and decentralised trial orchestration.
Emerging players
- Medable: Medable offers a decentralised and hybrid clinical trial platform with eCOA, eConsent, telehealth and wearable integration — competing with Atom5™ for sponsor and CRO DCT deployments, particularly among emerging biopharma sponsors.
- Castor: Castor provides an eClinical platform with ePRO and decentralised trial capabilities aimed at academic and biotech sponsors. It overlaps with Aparito's Atom5™ in ePRO and patient data capture but lacks Aparito's validated video COA library.
- Koneksa Health: Koneksa Health develops digital biomarkers and wearable-derived endpoints for clinical trials, overlapping with Aparito's computer-vision and wearable analytics capabilities within Atom5™, particularly in neuroscience and rare disease.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Aparito social profiles
Digital presenceAparito compliance and trust
Trust signalCompliance6 records
Aparito financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aparito leadership team
Management profileNumber of profiles
Profiles3 records
Aparito funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aparito M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aparito
What does Aparito do?
Aparito provides the Atom5 eCOA (electronic Clinical Outcome Assessment) platform that digitizes clinical trials by capturing patient data via video assessments, ePROs (electronic Patient-Reported Outcomes), wearable devices, telemedicine, and eConsent. The platform supports decentralized and hybrid clinical trials for pharmaceutical sponsors, CROs, and academic research groups across 193 countries and 125 languages, with over 800 configurations and compliance to FDA 21 CFR Part 11, HIPAA, GDPR, ISO 13485, and ISO 27001.
Is Aparito a public or private company?
Aparito is a private company. It is classified as corporate owned and is currently acquired.
When was Aparito founded?
Aparito was founded in 2014. It employs 11 to 50 people.
Where is Aparito based?
Aparito is headquartered in Wrexham, United Kingdom, in the Europe region.
How does Aparito make money?
Four revenue lines are on record. Enterprise SaaS subscription (Atom5™ eCOA platform) is the primary driver. The others are professional services & data science consulting, patient Group Accelerator / co-development partnerships and enterprise software licensing / study configuration.
Who are Aparito's main competitors?
Direct peers on record are Medidata Solutions, Clario, Signant Health, Science 37 and ObvioHealth. Broad incumbents are Oracle Health Sciences (Clinical One / Phase Forward) and Veeva Systems. Emerging players are Medable, Castor and Koneksa Health.
Does Aparito have an API?
Yes. Atom5™ integrates with any device that has an available API/SDK, such as wearable or medical devices. The platform can also integrate with other Electronic Data Capture (EDC) systems or provide raw data exports in custom formats. No public developer-facing documentation URL was specified in the source material.
What industry is Aparito in?
Aparito's product category is Clinical Trial Technology. Its primary akta.pro industry code is HLACAOAA, Electronic Data Capture (EDC) Platforms, with a secondary code of HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection. Its NAICS code is 541714 and its SIC code is 2834.